Pulmonary Solid and Granular Adenocarcinomas Expressing HepPar1/CPS1: Highly Aggressive Tumors Exhibiting Mitochondrial Adaptation to STK11 Mutations Rather Than Hepatoid Differentiation
Modern Pathology · 2026-04 · 39 (4) · 100965
DOI: 10.1016/j.modpat.2026.100965 ↗Kurz gefasst
Fachartikel in der Zeitschrift Modern Pathology, 2026-04. Verfasst von Christopher A Febres-Aldana und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program,…. Hauptthemen laut MEDLINE: Lung Neoplasms, Protein Serine-Threonine Kinases, Carbamoyl-Phosphate Synthase (Ammonia), Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Marie-Josée and Henry R. Kravis Center for Molecular Oncology, NCI.
Abstract (Originalsprache)
Hepatoid lung carcinomas, similar to hepatoid carcinomas of other sites, are defined as extrahepatic tumors exhibiting divergent hepatocellular differentiation. Uniquely, hepatoid carcinomas of lung origin are reported to commonly express only hepatocyte paraffin 1 (HepPar1)-a hepatocellular marker, which recognizes mitochondrial enzyme carbamoyl-phosphate synthetase-1 (CPS1). Recently, HepPar1/CPS1 was found to accumulate in lung adenocarcinomas (LUADs) harboring STK11mutations, presumably as a genotype-associated metabolic adaptation. The impact of these insights on the concept of hepatoid lung carcinoma has not been explored. Here, we performed a detailed clinicopathologic and genomic analysis of carcinomas prospectively regarded as hepatoid with isolated HepPar1 expression (n = 17). We found that although robustly positive for HepPar1, these tumors were entirely negative for an extended panel of other hepatocellular markers (alpha-fetoprotein, Arginase1, Glypican3, and albumin-in situ hybridization). Morphologically, tumors exhibited solid-trabecular architecture with expanded granular-vacuolated-clear cytoplasm, thus evoking hepatoid morphology; however, focal-to-moderate intracytoplasmic mucin was consistently present, and hepatoid resemblance was variable. Pneumocytic markers (TTF1 and Napsin A) were entirely negative (except for cytoplasmic TTF1), commonly leading to diagnostic challenges at metastatic sites. Remarkably, next-generation sequencing revealed invariable STK11 mutations/loss (P 2.5K). Patient survival was dismal (median, 5.8 vs 25 months for stage-matched LUAD, P = .0002). Tumors harbored high mitochondrial content by electron microscopy and other methods. For comparison, we reviewed conventional, predominantly acinar LUAD with HepPar1 expression (n = 22) and found that they also lacked any other hepatocellular markers, had invariable STK11 mutations/loss, increased granular cytoplasm, lower TTF1, and poor prognosis. We conclude that isolated HepPar1 expression in LUAD reflects mitochondrial adaptation to STK11 mutations rather than bona fide hepatocellular differentiation, and that HepPar1-expressing solid and granular adenocarcinomas represent an undifferentiated (solid, TTF1 negative) variant in this spectrum of tumors. Recognition of these tumors is warranted due to their exceptionally aggressive behavior, distinct pathogenomic features, and common association with diagnostic challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York; Laborator…
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Pathology and Laboratory Medicine, New York-Presbyterian Hospital and Weill Cornell Medical College, New York, New York.
- Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
- Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
- Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Förderung
- Marie-Josée and Henry R. Kravis Center for Molecular Oncology
- NCI
Zitieren
APA
Febres-Aldana, C. A., Vanderbilt, C. M., Aly, R., Saliba, M., Seshan, S. V., Frosina, D., Jungbluth, A. A., Richards, A. L., Bodd, F., Wilson, C., Park, K. J., Kezlarian-Sachs, B., Ladanyi, M., Cui, C., Rudin, C. M., Baine, M. K., Travis, W. D., Chang, J. C., Srivastava, A., & Rekhtman, N. (2026). Pulmonary Solid and Granular Adenocarcinomas Expressing HepPar1/CPS1: Highly Aggressive Tumors Exhibiting Mitochondrial Adaptation to STK11 Mutations Rather Than Hepatoid Differentiation. Modern Pathology, 39(4), 100965. https://doi.org/10.1016/j.modpat.2026.100965
Vancouver
Febres-Aldana CA, Vanderbilt CM, Aly R, Saliba M, Seshan SV, Frosina D, et al. Pulmonary Solid and Granular Adenocarcinomas Expressing HepPar1/CPS1: Highly Aggressive Tumors Exhibiting Mitochondrial Adaptation to STK11 Mutations Rather Than Hepatoid Differentiation. Modern Pathology. 2026;39(4):100965. doi:10.1016/j.modpat.2026.100965
BibTeX
@article{FebresAldana2026,
author = {Febres-Aldana, Christopher A and Vanderbilt, Chad M and Aly, Rania and Saliba, Maelle and Seshan, Surya V and Frosina, Denise and Jungbluth, Achim A and Richards, Allison L and Bodd, Francis and Wilson, Christina and Park, Kay J and Kezlarian-Sachs, Brie and Ladanyi, Marc and Cui, Can and Rudin, Charles M and Baine, Marina K and Travis, William D and Chang, Jason C and Srivastava, Amitabh and Rekhtman, Natasha},
title = {Pulmonary Solid and Granular Adenocarcinomas Expressing HepPar1/CPS1: Highly Aggressive Tumors Exhibiting Mitochondrial Adaptation to STK11 Mutations Rather Than Hepatoid Differentiation},
journal = {Modern Pathology},
year = {2026},
volume = {39},
number = {4},
pages = {100965},
doi = {10.1016/j.modpat.2026.100965}
}
EUVIMED